Picture of Pliant Therapeutics logo

PLRX — Pliant Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Pliant Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Pliant Therapeutics Inc  PLRX.OQ  reported a quarterly
adjusted
loss of 78 cents​​ per share for the quarter ended in March,
lower than the same quarter last year, when the company reported
EPS of -67 cents.  The mean expectation of thirteen analysts for
the quarter was for a loss of 77 cents per share. Wall Street
expected results to range from -83 cents to -66 cents per share.
    * Reported revenue was zero​; analysts expected $464.50
thousand. 
    * Pliant Therapeutics Inc's reported EPS for the quarter was
a
loss of 78 cents​.
    * The company reported a quarterly loss of $46.96 million.
    * Pliant Therapeutics Inc shares had fallen by 7.4% this
quarter and lost 23.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $41.00 
This summary was machine generated from LSEG data May 7 at 12:20
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.77          -0.78          Missed
 Dec. 31 2023      -0.81          -0.69          Beat
 Sep. 30 2023      -0.77          -0.70          Beat
 Jun. 30 2023      -0.71          -0.70          Beat

Recent news on Pliant Therapeutics

See all news